30 years of HER3: From basic biology to therapeutic interventions

HER3 is a pseudo-kinase member of the EGFR family having a role in both tumor progression and drug resistance. Although HER3 was discovered more than 30 years ago, no therapeutic interventions have reached clinical approval to date. Since the evidence of the importance of HER3 is accumulating, increased amount of preclinical and clinical trials with HER3 targeting agents are emerging. In this review article, we discuss the most recent HER3 biology in tumorigenic events and drug resistance, and overview the current and emerging strategies to target HER3.